"Hemophilia A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The classic hemophilia resulting from a deficiency of factor VIII. It is an inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhage.
| Descriptor ID |
D006467
|
| MeSH Number(s) |
C15.378.100.100.500 C15.378.100.141.500 C15.378.463.500 C16.320.099.500
|
| Concept/Terms |
Hemophilia A- Hemophilia A
- Hemophilia As
- Hemophilia, Classic
- Hemophilia
- Hemophilia A, Congenital
- Congenital Hemophilia A
- Congenital Hemophilia As
- Hemophilia As, Congenital
- Classic Hemophilia
- Classic Hemophilias
- Hemophilias, Classic
- Haemophilia
Autosomal Hemophilia A- Autosomal Hemophilia A
- As, Autosomal Hemophilia
- Autosomal Hemophilia As
- Hemophilia A, Autosomal
- Hemophilia As, Autosomal
Factor VIII Deficiency- Factor VIII Deficiency
- Factor 8 Deficiency, Congenital
- Factor VIII Deficiency, Congenital
- Deficiency, Factor VIII
|
Below are MeSH descriptors whose meaning is more general than "Hemophilia A".
Below are MeSH descriptors whose meaning is more specific than "Hemophilia A".
This graph shows the total number of publications written about "Hemophilia A" by people in this website by year, and whether "Hemophilia A" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 1 | 3 |
| 1995 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 2 | 0 | 2 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hemophilia A" by people in Profiles.
-
Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors. Haemophilia. 2022 Jul; 28(4):548-556.
-
Management of Patients With Hemophilia Undergoing Cardiac Surgery. J Cardiothorac Vasc Anesth. 2022 02; 36(2):539-541.
-
In vitro effects of emicizumab on activated clotting time in blood samples from cardiac surgical patients. Haemophilia. 2022 Jan; 28(1):183-190.
-
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. Haemophilia. 2021 Nov; 27(6):921-931.
-
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors. Haemophilia. 2021 Nov; 27(6):911-920.
-
Hemophilia: A Review of Perioperative Management for Cardiac Surgery. J Cardiothorac Vasc Anesth. 2022 01; 36(1):246-257.
-
Perioperative Coagulation Management of a Hemophilia A Patient During Cardiac Surgery. Semin Cardiothorac Vasc Anesth. 2017 Dec; 21(4):312-320.
-
Extended half-life factor VIII for immune tolerance induction in haemophilia. Haemophilia. 2016 Nov; 22(6):e552-e554.
-
Rituximab for treatment of inhibitors in haemophilia A. A Phase II study. Thromb Haemost. 2014 Sep 02; 112(3):445-58.
-
Successful Perioperative Management of Severe Bleeding From Undiagnosed Acquired Factor VIII Inhibitors. J Cardiothorac Vasc Anesth. 2015; 29(3):731-4.